143 related articles for article (PubMed ID: 12130509)
1. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma.
Chiriva-Internati M; Wang Z; Salati E; Bumm K; Barlogie B; Lim SH
Blood; 2002 Aug; 100(3):961-5. PubMed ID: 12130509
[TBL] [Abstract][Full Text] [Related]
2. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma.
Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH
Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264
[TBL] [Abstract][Full Text] [Related]
3. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk.
Chiriva-Internati M; Wang Z; Xue Y; Bumm K; Hahn AB; Lim SH
Eur J Immunol; 2001 Aug; 31(8):2277-83. PubMed ID: 11477539
[TBL] [Abstract][Full Text] [Related]
4. Tumor vaccine for ovarian carcinoma targeting sperm protein 17.
Chiriva-Internati M; Wang Z; Salati E; Timmins P; Lim SH
Cancer; 2002 May; 94(9):2447-53. PubMed ID: 12015770
[TBL] [Abstract][Full Text] [Related]
5. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
Wen YJ; Min R; Tricot G; Barlogie B; Yi Q
Blood; 2002 May; 99(9):3280-5. PubMed ID: 11964294
[TBL] [Abstract][Full Text] [Related]
6. Umbilical cord blood-derived dendritic cells infected by adenovirus for SP17 expression induce antigen-specific cytotoxic T cells against NSCLC cells.
Liu Y; Tian X; Jiang S; Ren X; Liu F; Yang J; Chen Y; Jiang Y
Cell Immunol; 2015; 298(1-2):18-24. PubMed ID: 26300426
[TBL] [Abstract][Full Text] [Related]
7. Identification of a sperm protein 17 CTL epitope restricted by HLA-A1.
Chiriva-Internati M; Wang Z; Pochopien S; Salati E; Lim SH
Int J Cancer; 2003 Dec; 107(5):863-5. PubMed ID: 14566839
[TBL] [Abstract][Full Text] [Related]
8. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.
Rew SB; Peggs K; Sanjuan I; Pizzey AR; Koishihara Y; Kawai S; Kosaka M; Ozaki S; Chain B; Yong KL
Clin Cancer Res; 2005 May; 11(9):3377-84. PubMed ID: 15867238
[TBL] [Abstract][Full Text] [Related]
9. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
[TBL] [Abstract][Full Text] [Related]
10. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
Wen YJ; Barlogie B; Yi Q
Blood; 2001 Mar; 97(6):1750-5. PubMed ID: 11238117
[TBL] [Abstract][Full Text] [Related]
11. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
12. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma.
Lim SH; Wang Z; Chiriva-Internati M; Xue Y
Blood; 2001 Mar; 97(5):1508-10. PubMed ID: 11222401
[TBL] [Abstract][Full Text] [Related]
13. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA.
Milazzo C; Reichardt VL; Müller MR; Grünebach F; Brossart P
Blood; 2003 Feb; 101(3):977-82. PubMed ID: 12393470
[TBL] [Abstract][Full Text] [Related]
14. Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma.
Jalili A; Ozaki S; Hara T; Shibata H; Hashimoto T; Abe M; Nishioka Y; Matsumoto T
Blood; 2005 Nov; 106(10):3538-45. PubMed ID: 16037388
[TBL] [Abstract][Full Text] [Related]
15. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes.
Azuma T; Otsuki T; Kuzushima K; Froelich CJ; Fujita S; Yasukawa M
Clin Cancer Res; 2004 Nov; 10(21):7402-12. PubMed ID: 15534117
[TBL] [Abstract][Full Text] [Related]
16. The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.
Schutt CA; Mirandola L; Figueroa JA; Nguyen DD; Cordero J; Bumm K; Judson BL; Chiriva-Internati M
Oncotarget; 2017 Nov; 8(59):100280-100287. PubMed ID: 29245977
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
[TBL] [Abstract][Full Text] [Related]
18. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics?
Dadabayev AR; Wang Z; Zhang Y; Zhang J; Robinson WR; Lim SH
Am J Hematol; 2005 Sep; 80(1):6-11. PubMed ID: 16138340
[TBL] [Abstract][Full Text] [Related]
20. Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.
Wu L; Zhang H; Jiang Y; Gallo RC; Cheng H
Proc Natl Acad Sci U S A; 2018 May; 115(19):E4453-E4462. PubMed ID: 29674449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
